Synopsis
Synopsis
0
VMF
0
FDF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Mls001401438
2. Chembl1895091
3. Hms2051p14
4. Hms2233m10
5. Ccg-101038
6. Nc00288
7. Smr000471620
Molecular Weight | 478.5 g/mol |
---|---|
Molecular Formula | C23H30N2O9 |
Hydrogen Bond Donor Count | 7 |
Hydrogen Bond Acceptor Count | 10 |
Rotatable Bond Count | 10 |
Exact Mass | 478.19513054 g/mol |
Monoisotopic Mass | 478.19513054 g/mol |
Topological Polar Surface Area | 166 Ų |
Heavy Atom Count | 34 |
Formal Charge | 0 |
Complexity | 507 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 2 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 1 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 3 |
GDUFA
DMF Review : Complete
Rev. Date : 2017-06-16
Pay. Date : 2017-05-10
DMF Number : 16628
Submission : 2003-06-03
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 30324
Submission : 2016-06-04
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 32936
Submission : 2018-07-27
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2019-09-19
Pay. Date : 2019-06-25
DMF Number : 33894
Submission : 2019-07-12
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2012-12-26
Pay. Date : 2012-12-03
DMF Number : 21357
Submission : 2008-02-22
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 12380
Submission : 1997-02-24
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2018-05-17
Pay. Date : 2018-03-19
DMF Number : 20178
Submission : 2007-04-24
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 14154
Submission : 1999-05-25
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 16241
Submission : 2002-11-13
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19202
Submission : 2006-02-21
Status : Active
Type : II
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
The acquisition of “Combihale” is expected to strengthen Mankind’s presence in the inhalation respiratory market segment. Daffy is a soap-free moisturising bar for infant babies.
Lead Product(s): Formoterol Fumarate,Fluticasone Propionate
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Combihale
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Mankind Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition February 16, 2022
Lead Product(s) : Formoterol Fumarate,Fluticasone Propionate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Mankind Pharma
Deal Size : Undisclosed
Deal Type : Acquisition
Mankind Pharma to Acquire Combihale and Daffy Brands From Dr Reddy's Laboratories
Details : The acquisition of “Combihale” is expected to strengthen Mankind’s presence in the inhalation respiratory market segment. Daffy is a soap-free moisturising bar for infant babies.
Brand Name : Combihale
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 16, 2022
Details:
Formoterol Fumarate is a long-acting bronchodilator used as a long-term treatment to prevent or decrease wheezing and trouble breathing caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema).
Lead Product(s): Formoterol Fumarate
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Formoterol Fumarate-Generic
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2022
Lead Product(s) : Formoterol Fumarate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Aucta Announces FDA Approval Of A Generic Version Of Perforomist® (formoterol fumarate) Inhalatio...
Details : Formoterol Fumarate is a long-acting bronchodilator used as a long-term treatment to prevent or decrease wheezing and trouble breathing caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchiti...
Brand Name : Formoterol Fumarate-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 01, 2022
Details:
Breztri Aerosphere is a combination of budesonide, glycopyrrolate and formoterol fumarate indicated for the maintenance treatment of patients with COPD.
Lead Product(s): Budesonide,Glycopyrronium Bromide,Formoterol Fumarate
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Breztri Aerosphere
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 23, 2024
Lead Product(s) : Budesonide,Glycopyrronium Bromide,Formoterol Fumarate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
AstraZeneca Pharma Pharma India to launch Breztri Aerosphere in Jan 2025
Details : Breztri Aerosphere is a combination of budesonide, glycopyrrolate and formoterol fumarate indicated for the maintenance treatment of patients with COPD.
Brand Name : Breztri Aerosphere
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 23, 2024
Details:
Two companies have a collaboration agreement to develop an environmentally friendly propellant for flutiform® (fluticasone propionate/formoterol fumarate) in a pMDI formulation.
Lead Product(s): Fluticasone Propionate,Formoterol Fumarate
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Flutiform
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Vectura Ltd
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 16, 2024
Lead Product(s) : Fluticasone Propionate,Formoterol Fumarate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Vectura Ltd
Deal Size : Undisclosed
Deal Type : Collaboration
Mundipharma, Vectura Plan to Reformulate flutiform® to Reduce Carbon Footprint
Details : Two companies have a collaboration agreement to develop an environmentally friendly propellant for flutiform® (fluticasone propionate/formoterol fumarate) in a pMDI formulation.
Brand Name : Flutiform
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 16, 2024
Details:
Under the agreement, Mankind Pharma will distribute AstraZeneca's anti-asthma inhaled corticosteroid drug Symbicort, (budesonide/formoterol) approved to treat asthma and COPD, in India.
Lead Product(s): Budesonide,Formoterol Fumarate
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Symbicort
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Mankind Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 13, 2024
Lead Product(s) : Budesonide,Formoterol Fumarate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Mankind Pharma
Deal Size : Undisclosed
Deal Type : Agreement
Mankind Pharma Enters Exclusive Pact to Distribute AstraZeneca's Symbicort in India
Details : Under the agreement, Mankind Pharma will distribute AstraZeneca's anti-asthma inhaled corticosteroid drug Symbicort, (budesonide/formoterol) approved to treat asthma and COPD, in India.
Brand Name : Symbicort
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 13, 2024
Details:
Breyna™ (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol is the first generic version of AstraZeneca's Symbicort drug-device combination product and is indicated for certain patients with asthma or chronic obstructive pulmonary disease (COPD).
Lead Product(s): Budesonide,Formoterol Fumarate
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Breyna
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 31, 2023
Lead Product(s) : Budesonide,Formoterol Fumarate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Viatris Announces Launch of Breyna™ (budesonide and formoterol fumarate dihydrate) Inhalation Ae...
Details : Breyna™ (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol is the first generic version of AstraZeneca's Symbicort drug-device combination product and is indicated for certain patients with asthma or chronic obstructive pulmonary disease...
Brand Name : Breyna
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 31, 2023
Details:
Duaklir (aclidinium bromide) and Duaklir (aclidinium bromide/formoterol) are inhaled respiratory medicines used for the maintenance treatment of COPD. Eklira is a LAMA and Duaklir is a combination therapy that contains both a LAMA and a long-acting beta2-agonist (LABA).
Lead Product(s): Aclidinium Bromide,Formoterol Fumarate
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Duaklir
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 25, 2022
Lead Product(s) : Aclidinium Bromide,Formoterol Fumarate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Duaklir (aclidinium bromide) and Duaklir (aclidinium bromide/formoterol) are inhaled respiratory medicines used for the maintenance treatment of COPD. Eklira is a LAMA and Duaklir is a combination therapy that contains both a LAMA and a long-acting beta2...
Brand Name : Duaklir
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 25, 2022
Details:
Luforbec (formoterol) oral inhalation is used to control wheezing, shortness of breath, and chest tightness caused by chronic obstructive pulmonary disease.
Lead Product(s): Formoterol Fumarate,Beclomethasone Dipropionate
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Luforbec
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 25, 2022
Lead Product(s) : Formoterol Fumarate,Beclomethasone Dipropionate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lupin's Arm Gets UK Regulator Nod for COPD Treatment
Details : Luforbec (formoterol) oral inhalation is used to control wheezing, shortness of breath, and chest tightness caused by chronic obstructive pulmonary disease.
Brand Name : Luforbec
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 25, 2022
Details:
Breyna (Budesonide and Formoterol Fumarate Dihydrate), first approved generic version of AstraZeneca's Symbicort, a drug-device combination product, is indicated for certain patients with asthma or COPD and will be available in 160 /4.5 and 80/4.5 mcg dosage strengths.
Lead Product(s): Budesonide,Formoterol Fumarate
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Breyna
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Kindeva Drug Delivery
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 16, 2022
Lead Product(s) : Budesonide,Formoterol Fumarate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Kindeva Drug Delivery
Deal Size : Not Applicable
Deal Type : Not Applicable
Viatris Inc. Announces Receipt of the First FDA Approval for Generic Version of Symbicort® Inhala...
Details : Breyna (Budesonide and Formoterol Fumarate Dihydrate), first approved generic version of AstraZeneca's Symbicort, a drug-device combination product, is indicated for certain patients with asthma or COPD and will be available in 160 /4.5 and 80/4.5 mcg do...
Brand Name : Breyna
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 16, 2022
Details:
U.S.FDA approved generic budesonide and formoterol fumarate dihydrate aerosol for treatment of two pulmonary health conditions: asthma in patients six years of age and older; and maintenance treatment of airflow obstruction and reducing exacerbations for patients with COPD.
Lead Product(s): Budesonide,Formoterol Fumarate
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Budesonide/Formoterol Fumarate Dihydrate-Generic
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 15, 2022
Lead Product(s) : Budesonide,Formoterol Fumarate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Approves First Generic of Symbicort to Treat Asthma and COPD
Details : U.S.FDA approved generic budesonide and formoterol fumarate dihydrate aerosol for treatment of two pulmonary health conditions: asthma in patients six years of age and older; and maintenance treatment of airflow obstruction and reducing exacerbations for...
Brand Name : Budesonide/Formoterol Fumarate Dihydrate-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 15, 2022
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?